UBS Maintains a 'Buy' on Cincinnati Bell (CBB); Unleash The CyrusOne
Get Alerts CBB Hot Sheet
Price: $15.48 --0%
Rating Summary:
1 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Rating Summary:
1 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Join SI Premium – FREE
UBS maintains a 'Buy' on Cincinnati Bell (NYSE: CBB) price target of $6.00 (from $4.25).
Analyst, Batya Levi, sees the company's recent move to spin-off its data center business, CyrusOne, by means of IPO (and assigning it as a REIT) will have positive implications. Levi expects Cincinnati Bell to use the approx. $300 million proceeds to pay down debt and possibly implement a dividend or buyback. Overall, the sum-of-the-parts suggests upside to the current stock price.
For an analyst ratings summary and ratings history on Cincinnati Bell click here. For more ratings news on Cincinnati Bell click here.
Shares of Cincinnati Bell closed at $4.45 yesterday.
Analyst, Batya Levi, sees the company's recent move to spin-off its data center business, CyrusOne, by means of IPO (and assigning it as a REIT) will have positive implications. Levi expects Cincinnati Bell to use the approx. $300 million proceeds to pay down debt and possibly implement a dividend or buyback. Overall, the sum-of-the-parts suggests upside to the current stock price.
For an analyst ratings summary and ratings history on Cincinnati Bell click here. For more ratings news on Cincinnati Bell click here.
Shares of Cincinnati Bell closed at $4.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Swiss Re (SREN:SW) (SSREY) to Hold
- AIB Group PLC (AIBG:ID) (AIBRF) PT Raised to EUR6 at Berenberg
- Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$23 at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, IPOsRelated Entities
UBS, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!